EUVIMEDEUVIMED entdecken
Multizentrische Studie

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study

Adam S Kittai iD, David Bond iD, Ying Huang, Seema A Bhat, Emily Blyth iD, John C Byrd iD, Julio C Chavez iD, Matthew S Davids iD, Jamie P Dela Cruz, Mark R Dowling, Caitlyn Duffy iD, Carrie Ho iD und 21 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.24.00033 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Adam S Kittai und 32 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, The Ohio State University, Columbus, OH. Hauptthemen laut MEDLINE: Antigens, CD19, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Outcomes for Richter transformation (RT) are poor with current therapies. The efficacy and safety of anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) for RT are not established. METHODS We performed an international multicenter retrospective study of patients with RT who received CAR-T. Patient, disease, and treatment characteristics were summarized using descriptive statistics, and modeling analyses were used to determine association with progression-free survival (PFS) and overall survival (OS). PFS and OS were estimated from the date of CAR-T infusion. RESULTS Sixty-nine patients were identified. The median age at CAR-T infusion was 64 years (range, 27-80). Patients had a median of four (range, 1-15) previous lines of therapy for CLL and/or RT, including previous Bruton tyrosine kinase inhibitor and/or BCL2 inhibitor therapy in 58 (84%) patients. The CAR-T product administered was axicabtagene ciloleucel in 44 patients (64%), tisagenlecleucel in 17 patients (25%), lisocabtagene maraleucel in seven patients (10%), and brexucabtagene autoleucel in one patient (1%). Eleven patients (16%) and 25 patients (37%) experienced grade ≥3 cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, respectively. The overall response rate was 63%, with 46% attaining a complete response (CR). After a median follow-up of 24 months, the median PFS was 4.7 months (95% CI, 2.0 to 6.9); the 2-year PFS was 29% (95% CI, 18 to 41). The median OS was 8.5 months (95% CI, 5.1 to 25.4); the 2-year OS was 38% (95% CI, 26 to 50). The median duration of response was 27.6 months (95% CI, 14.5 to not reached) for patients achieving CR. CONCLUSION CAR-T demonstrates clinical efficacy for patients with RT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, CD19Immunotherapy, AdoptiveReceptors, Chimeric AntigenHumansRetrospective StudiesMaleMiddle AgedAgedAdultFemaleAged, 80 and overLeukemia, Lymphocytic, Chronic, B-CellProgression-Free Survival

Substanzen

Antigens, CD19Receptors, Chimeric AntigenCD19 molecule, human

Autor:innen und Institutionen

  • Division of Hematology, The Ohio State University, Columbus, OH.
  • Blood Transplant and Cell Therapies Program, Westmead Hospital Department of Haematology, Westmead, NSW, Australia.
  • Department of Internal Medicine, University of Cincinnati, Cincinnati, OH.
  • Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

ORCID-Profile: Adam S Kittai, David Bond, Emily Blyth, John C Byrd, Julio C Chavez, Matthew S Davids, Caitlyn Duffy, Carrie Ho, Caron Jacobson, Nitin Jain, Kevin H Lin, Zulfa Omer, Erin Parry, Manoj Rai, Kerry A Rogers, Aditi Saha, Levanto Schachter, Hamish Scott, Jayastu Senapati, Mazyar Shadman, Tanya Siddiqi, Deborah M Stephens, William Wierda, Jennifer A Woyach

Zitieren

APA

Kittai, A. S., Bond, D., Huang, Y., Bhat, S. A., Blyth, E., Byrd, J. C., Chavez, J. C., Davids, M. S., Dela Cruz, J. P., Dowling, M. R., Duffy, C., Ho, C., Jacobson, C., Jaglowski, S., Jain, N., Lin, K. H., Miller, C., McCarthy, C., Omer, Z., …, & Thompson, P. A. (2024). Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00033

Vancouver

Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, et al. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. Journal of Clinical Oncology. 2024. doi:10.1200/jco.24.00033

BibTeX
@article{Kittai2024,
  author = {Kittai, Adam S and Bond, David and Huang, Ying and Bhat, Seema A and Blyth, Emily and Byrd, John C and Chavez, Julio C and Davids, Matthew S and Dela Cruz, Jamie P and Dowling, Mark R and Duffy, Caitlyn and Ho, Carrie and Jacobson, Caron and Jaglowski, Samantha and Jain, Nitin and Lin, Kevin H and Miller, Cecelia and McCarthy, Christine and Omer, Zulfa and Parry, Erin and Rai, Manoj and Rogers, Kerry A and Saha, Aditi and Schachter, Levanto and Scott, Hamish and Senapati, Jayastu and Shadman, Mazyar and Siddiqi, Tanya and Stephens, Deborah M and Vanguru, Vinay and Wierda, William and Woyach, Jennifer A and Thompson, Philip A},
  title = {Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.24.00033}
}
Kostenlos starten →